Skip to main content

Table 8 QoL assessement (EORTC QLQ C30 and EORTC QLQ BR 23) by site of metastases and time (Mean scores and standard errors)

From: Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial

 

Baseline

6 Mo

12 Mo

18 Mo

24 Mo

 

QOL domain

bone only

visceral +/- bone

bone only

visceral +/- bone

bone only

visceral +/- bone

bone only

visceral +/- bone

bone only

visceral +/- bone

p-Valueb

Physical Functioning

59.8 (5.0)

77.9 (3.9)

74.3 (5.6)

73.1 (4.2)

68.6 (5.5)

73.4 (4.2)

67.9 (6.7)

67.9 (5.3)

60.0 (6.2)

71.1 (5.2)

0.5868

Role Functioning

55.9 (6.5)

74.8 (5.2)

62.0 (7.6)

65.1 (5.6)

65.0 (6.8)

67.8 (5.3)

67.1 (8.4)

62.6 (6.9)

61.7 (9.2)

63.9 (7.8)

0.9142

Emotional Functioning

58.1 (4.8)

61.6 (3.8)

70.2 (6.1)

65.7 (4.4)

68.9 (5.1)

72.2 (4.0)

66.9 (6.1)

67.9 (4.9)

63.8 (6.0)

75.2 (5.2)

0.6476

Cognitive Functioning

89.4 (3.2)

91.1 (2.5)

82.3 (4.8)

81.2 (3.6)

83.1 (4.9)

81.7 (3.9)

79.5 (5.7)

80.5 (4.5)

77.4 (5.4)

81.3 (4.7)

0.9127

Social Functioning

69.3 (6.3)

72.8 (5.0)

81.0 (6.9)

70.0 (5.0)

77.7 (6.4)

77.7 (5.1)

69.5 (7.7)

72.4 (6.4)

65.3 (5.5)

84.5 (4.7)

0.6739

Global health status/QoL

53.2 (5.0)

55.3 (3.9)

65.0 (5.7)

65.6 (4.0)

65.5 (4.8)

69.5 (3.8)

60.8 (6.6)

70.0 (5.5)

57.4 (5.3)

74.3 (4.8)

0.1450

Fatigue

43.9 (5.5)

32.2 (4.3)

40.9 (6.9)

37.8 (5.0)

45.1 (6.2)

36.1 (4.9)

37.7 (6.9)

35.4 (5.6)

41.5 (6.3)

36.7 (5.3)

0.5008

Nausea/Vomiting

7.6 (3.2)

8.1 (2.5)

3.1 (3.1)

8.7 (2.3)

13.6 (4.2)

5.6 (3.3)

7.7 (3.6)

6.7 (2.9)

15.8 (5.2)

4.8 (4.4)

0.2928

Pain

52.0 (6.4)

24.6 (5.0)

28.3 (6.7)

25.7 (4.9)

29.1 (5.7)

22.4 (4.5)

31.7 (7.0)

27.0 (5.6)

38.6 (6.7)

21.9 (5.5)

0.2660

Dyspnoea

22.3 (5.2)

14.4 (4.0)

24.7 (6.4)

22.5 (4.6)

25.0 (6.6)

25.8 (5.2)

44.4 (9.4)

30.1 (7.6)

38.4 (7.5)

26.1 (6.1)

0.3687

Insomnia

33.3 (6.1)

40.1 (4.8)

19.1 (7.1)

34.4 (5.0)

28.0 (6.9)

34.0 (5.4)

28.9 (7.4)

32.3 (6.1)

35.0 (7.1)

26.8 (6.1)

0.5571

Appetite loss

22.2 (6.2)

22.1 (4.9)

16.1 (7.0)

17.8 (5.1)

19.0 (6.0)

16.6 (4.7)

12.9 (5.3)

15.5 (4.4)

22.9 (5.4)

11.5 (4.8)

0.6599

Constipation

22.9 (5.6)

17.9 (4.5)

22.4 (7.6)

23.2 (5.6)

17.1 (6.4)

23.7 (5.0)

12.3 (7.0)

20.0 (5.6)

28.1 (7.3)

12.4 (6.4)

0.9843

Diarhoea

3.3 (3.6)

8.3 (2.8)

4.2 (5.5)

12.6 (4.1)

9.6 (4.1)

8.5 (3.2)

8.1 (5.5)

11.5 (4.4)

7.1 (3.5)

5.3 (2.9)

0.6297

Financial Problems

7.6 (4.9)

15.5 (3.8)

9.9 (6.5)

24.2 (4.7)

20.6 (6.6)

24.0 (5.2)

23.8 (7.1)

26.6 (5.6)

18.7 (5.4)

18.8 (4.5)

0.4584

Body image

81.8 (4.0)

84.1 (3.3)

80.4 (6.3)

72.1 (4.7)

83.7 (4.6)

81.8 (3.6)

74.5 (5.7)

82.0 (4.6)

68.1 (5.9)

78.1 (4.8)

0.7569

Sexual functioning

15.7 (4.8)

15.9 (4.0)

17.5 (5.2)

17.5 (3.9)

11.4 (6.1)

26.0 (4.9)

13.7 (6.2)

24.9 (5.2)

14.0 (6.2)

22.2 (5.4)

0.1794

Future perspective

33.2 (6.2)

35.5 (5.1)

42.6 (7.3)

36.3 (5.3)

47.2 (7.3)

48.1 (5.7)

45.8 (8.3)

38.7 (6.7)

37.1 (7.7)

66.8 (6.7)

0.5522

Systematic therapy

21.8 (3.1)

14.9 (2.5)

26.1 (4.9)

31.6 (3.6)

22.9 (3.3)

17.5 (2.6)

26.9 (4.4)

23.2 (3.5)

26.0 (3.6)

20.3 (3.0)

0.5631

Breast symptoms

22.4 (3.8)

18.8 (3.2)

15.4 (3.8)

13.9 (2.8)

13.0 (3.0)

11.2 (2.3)

10.1 (4.3)

12.4 (3.4)

13.9 (3.9)

5.3 (3.4)

0.4986

Arm symptoms

21.4 (3.4)

12.6 (2.7)

24.4 (5.2)

19.4 (3.9)

22.3 (4.6)

17.4 (3.6)

29.4 (5.6)

20.7 (4.4)

21.0 (5.1)

14.5 (4.2)

0.2467

Hair loss

7.2 (2.7)

1.2 (2.2)

29.7 (8.5)

30.0 (6.3)

16.2 (5.3)

2.6 (3.9)

23.8 (5.9)

7.1 (4.6)

15.0 (7.9)

9.7 (6.5)

0.1468

  1. Legends: QoL: Quality of life
  2. aEstimates for themean scores estimated via the linearmixedmodeling expressed in absolute score points of the scale. Higher values for the symptomscales (Diarrhea, Loss of appetite, Nausea/vomiting, Fatigue) represent aworse level of symptoms. Higher values for the global health/Quality of Life scale represents a better level of functioning
  3. bp-value belongs to the comparison between metastase location groups